Get 40% Off
😲 Missed the +20.8% surge in our stock strategy last month? Not again! Get premium insightsGet 40% Off Now

GC Biopharma Corp (006280)

Seoul
Currency in KRW
Disclaimer
121,400
+500(+0.41%)
Delayed Data
Fair Value
Unlock Value
Day's Range
120,000122,000
52 wk Range
93,000140,600
Bid/Ask
121,400.00 / 121,500.00
Prev. Close
120,900
Open
120,800
Day's Range
120,000-122,000
52 wk Range
93,000-140,600
Volume
12,782
Average Vol. (3m)
17,691
1-Year Change
2.2%
Shares Outstanding
11,413,178
Fair Value
Unlock
Dividends Payment Streak
Unlock
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Daily
Weekly
Monthly
More

People Also Watch

8,000
138930
-0.37%
80,900
138040
-1.82%
47,000
004000
+0.21%
6,240
001740
-0.16%
25,850
001120
-1.34%
How do you feel today about 006280?
Vote to see community's results!
or

GC Biopharma Corp Company Profile

GC Biopharma Corp., a biopharmaceutical company, develops and sells pharmaceutical drugs in South Korea and internationally. It provides over-the-counter drugs, such as Acustop Cataplasma for Analgesic and anti-inflammatory effect; Kenhancer plaster for anti-inflammatory; and Zenol Cool Type and Zenol Mild Hot Type drugs to treat anti-inflammatory and pain relief. The company also offers Albumin-GCC injection (inj.) for hypoalbuminemia and shock in acute hemorrhage, as well as low synthesis of albumin; Antithrombin-III (AT-III) inj. for hereditary antithrombin-III deficiency; Facnyne inj. for hemophilia B; Fibrinogen to treat hypofibrinogenemia and afibrinogenemia; Gamma Globulin for hypogammaglobulinemia and agammaglobulinemia; GCFLU Quadrivalent and GC FLU pre-filled syringe inj. for prevention of influenza; GreenGene F inj. for bleeding symptom control and hemostasis for persons with hemophilia A; GreenGene inj. for bleeding episodes induced by hemophilia A; Greenplast Q for sealing tissues and closing open wounds; and Green-VIII inj. for Hemophilia A with supplies of blood coagulation factor VIII. In addition, it provides Hepabig inj. for hepatitis B; Histobulin to treat bronchial asthma; Hunterase for hunter syndrome; I.V. Hepabig inj. for prevention of hepatitis B recurrence in patients following liver transplantation; I.V.-Globulin SN inj. 5%; Immuncell-LC to treat liver cancer; Sero-Tet inj. for prophylaxis of tetanus and the reduction of tetanus symptoms; Shinbaro for anti-inflammation, pain relief, and osteoarthritis; Varicella Vaccine-GCC inj. for prophylaxis of varicella; and Varicella-Zoster Immune Globulin-GCC inj. for passive immunity to susceptible immunodeficient children exposed to varicella. The company was founded in 1967 and is headquartered in Yongin-Si, South Korea. GC Biopharma Corp. is a subsidiary of Green Cross Holdings Corporation.

Employees
2087
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.